Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois. The company trades on NCM exchange. The company headquarter is located in Chicago, United States. The company was established in the 2017.

TickerCDIO
Long NameCardio Diagnostics Holdings, Inc.
Short NameCardio Diagnostics Holdings